Quality of life, nutritional status and gastrointestinal hormone profile following the Whipple procedure.

Pancreatic cancer is the second commonest gastrointestinal cancer, after colorectal cancer, in Canada, and most other European and North American countries. Unfortunately, most patients present with advanced locoregional or metastatic disease. For the 10-20% of patients who have localized disease, pancreatic resection is generally the preferred treatment option. Because pancreaticoduodenectomy can be performed safely in expert hands, it has become a more accepted procedure for patients with pancreatic cancer. Furthermore, it has also meant that there is increasing scrutiny of the longterm outcome of patients, especially their nutritional status and quality of life. In a study of 25 unselected patients who had a Whipple procedure at least 6 months previously and were not known to have residual or recurrent disease, patients appeared to have few gastrointestinal symptoms compared to control patients. However, none of the subjects appeared to be clinically malnourished. Dietary intake and lean body mass were comparable to that of the control group. Quality of life was excellent in these patients. The mean utilities were 0.98 and 1.0 suggesting near normal wellbeing. Similarly, results using the SIP and GIQLI suggested no/minimal impairment in general wellbeing and gastrointestinal function. Two other studies suggest that median survival and performance status are improved in patients having a resection, but it may be due to their disease being more favorable rather than the treatment being beneficial. Further studies objectively assessing the quality of life of all patients undergoing treatment for pancreatic cancer at the various disease stages are required.